Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 11/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | METAP2 | P50579 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3554581 | 0.96 | KDM4E (0.54) | SLC16A3KDM4EALDH1A1METAP2KMT2A | |
| SCHEMBL3556581 | 0.93 | SLC16A3 (0.58) | SLC16A3KDM4EALDH1A1METAP2KMT2A | |
| SCHEMBL3554689 | 0.91 | SLC16A3 (0.64) | SLC16A3KDM4EALDH1A1METAP2KMT2A | |
| SCHEMBL3564778 | 0.91 | SLC16A3 (0.64) | SLC16A3KDM4EALDH1A1METAP2TSHR | |
| SCHEMBL3554341 | 0.91 | CCR2 (0.59) | SLC16A3KDM4EALDH1A1METAP2KMT2A | |
| SCHEMBL3557805 | 0.89 | SLC16A3 (0.65) | SLC16A3KDM4EALDH1A1METAP2KMT2A | |
| SCHEMBL3556080 | 0.89 | SLC16A3 (0.56) | SLC16A3KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL3552944 | 0.89 | SLC16A3 (0.56) | SLC16A3ALDH1A1KMT2AMEN1 | |
| SCHEMBL3555224 | 0.88 | ACLY (0.55) | SLC16A3KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL3558585 | 0.88 | SLC16A3 (0.58) | SLC16A3KDM4EALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | SLC16A3 425/4885KDM4E 1045/4885ALDH1A1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.